Intralytix is located at 8681 Robert Fulton Drive, Columbia MD 21046, US. The 33,000-square-foot building has production facilities with capabilities for:
Long-term cryogenic storage of hundreds of phages and thousands of bacteria strain stocks;
Manufacturing and production of phages in 1,500 L fermentation vessels with room to expand;
Read the full text
Customized large volume phage product mixing;
Commercial scale spray drying capabilities;
And, high-throughput automatic filling.
Intellectual Property (IP) Portfolio
Intralytix is headed by Dr. Alexander Sulakvelidze, President and chief executive officer.
Intralytix's patent strategy is based on a multi-pronged approach, which provides broad and strong protection ranging from protecting specific bacteriophages that serve as the cornerstone of various company products to methods and applications of those bacteriophages in various settings. As of 2022, Intralytix has:
15 issued/allowed patents;
Several pending patent applications worldwide.
Intralytix Products
Food Safety Products
These phage-based products are designed to be applied to food before, during, or after processing or packaging, as appropriate. They work by targeting and killing specific human (including animal) pathogenic bacteria that may be present in food. These products do not alter the color, taste, or smell of food in any way.
CampyShield targets Campylobacter jejuni and Campylobacter coli which cause campylobacteriosis. Used to treat raw red med (e.g., whole carcasses, primal and subprimal, etc.) and raw poultry.
ListShield targets Listeria monocytogenes which causes listeriosis. Used to treat ready-to-eat foods (e.g., meat, cheese, and fish), raw meats, fruits, and vegetables.
SalmoFresh targets most common, highly pathogenic Salmonella enterica serotypes. Used to treat poultry products, fish, shellfish, fresh and processed fruits and vegetables, and ready-to-eat and raw red meat carcasses and parts and trimmings.
ShigaShield targets Shigella strains responsible for the majority of foodborne disease, including S. flexneri, S. sonnei, and S. dysenteriae. Used to treat ready-to-eat meats, fish and shellfish, fresh and processed fruits, fresh and processed vegetables, and dairy products.
EcoShield PX targets E. coli O157:H7 and Shiga toxin-producing E. coli (STEC). Used to treat various foods including beef and ground beef, chicken, fish, and fruits and vegetables.
Ecolicide targets E. coli O157:H7 in pet food.
SalmoLyse targets S. enterica in pet food.
ListPhage targets L. monocytogenes in pet food.
Pre-Harvest Intervention Products
These food safety-related products are designed to be applied to live animals prior to entering the processing facility, through spray application to the animals' hide, skin, or feathers. After application, the phages act to reduce the contamination of specific target bacteria, if present on the animal, and prevent it from entering the facility.
Ecolicide PX targets E. coli O157:H7 contamination on the hides of live animals.
Therapeutic Products
ShigActive targets Shigella species. ShigActive has been shown to be efficacious in mice. In 2020, Intralytix was awarded a clinical trial grant by NIAID to assess the safety and efficacy of ShigActive for the management of shigellosis (AI 148054).
EcoActive targets adherent-invasive E. coli (AIEC) associated with inflammation in Crohn's disease. A Phase 1/2a clinical trial is currently enrolling at the Mount Sinai Hospital in New York, NY and at the Johns Hopkins University in Baltimore, MD. (ClinicalTrials.gov Identifier: NCT03808103).
VRELysin targets vancomycin-resistant Enterococcus (VRE), which in turn, may prevent subsequent infection as well as nosocomial spread (NCT05715619). A Phase 1/2a clinical trial is expected to start in Q3 2023.
